The FDA gave its blessing to 35 new drugs during fiscal 2012, a number that matches last year's total--and that put the agency ahead of other regulators in approving new therapies first. But is the FDA's record a sign that biopharma has more winners on tap? Or simply that the agency has accelerated its own processes? Report